No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 11 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for MDxHealth S.A. (MDXH) stock was $0.60 as of Oct 6, 2026, 10:28 AM EDT, up 0.67% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -87.5% · 3-year avg -36.2%/yr
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union.
Medical - Diagnostics & Research · Herstal, WA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2023-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2023-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.18
vs Estimate
$-0.19
Revenue
$27.21M
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MDXH | $30.86M | $0.60 | +0.67% | -87.47% | N/A | N/A | N/A |
| 2BYSI | $31.16M | $0.76 | -3.58% | -54.91% | -44.30% | N/A | vs MDXH |
| 3MIRA | $31.29M | $0.74 | +1.24% | -45.36% | N/A | N/A | vs MDXH |
| 4CNTX | $31.32M | $0.34 | +1.31% | -69.24% | N/A | N/A | vs MDXH |
| 5BDMD | $31.36M | $0.74 | N/A | -63.41% | N/A | N/A | vs MDXH |
| 6CRVO | $29.63M | $3.20 | -3.32% | -61.36% | -38.25% | -53.96% | vs MDXH |
N/A
vs Estimate
$26.14M
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$0.60
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $-0.10 | $-0.09 | $-0.08 | 3 |
| Quarter ending Jun 2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Quarter ending Dec 2027 | $-0.05 | $-0.05 | $-0.04 | 1 |
| Quarter ending Jun 2028 | $-0.01 | $-0.01 | $-0.01 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.52 | $-0.51 | $-0.49 | 3 |
| FY 2027 | $-0.35 | $-0.28 | $-0.21 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $27.56M | $28.27M | $28.75M | 3 |
| Quarter ending Jun 2027 | $30.45M | $31.23M | $31.77M | 1 |
| Quarter ending Dec 2027 | $32.63M | $33.46M | $34.04M | 1 |
| Quarter ending Jun 2028 | $36.71M | $37.65M | $38.30M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $108.03M | $111.19M | $114.31M | 4 |
| FY 2027 | $122.25M | $125.82M | $129.35M | 4 |
